Amyloid light-chain (AL) amyloidosis is a rare systemic disease of high unmet need caused by plasma cell dyscrasia. Timely diagnosis of this condition is essential, however many challenges surround disease recognition amongst clinicians, and the current treatment landscape lacks effective therapies. Expert Giovanni Palladini discusses new antibodies with the potential to target amyloid deposits, that have shown encouraging results in early phase studies and are now progressing into late-stage development.
Latest articles
All articles
